CSIMarket
 


Invitae Corporation  (NVTA)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

NVTA's Operating Income Growth by Quarter and Year

Invitae's Operating Income results by quarter and year




NVTA Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -94.90 -214.57 -331.48
III Quarter September -980.19 -289.95 -193.31 -80.82
II Quarter June -226.46 -2,520.33 128.61 -142.08
I Quarter March -175.37 -213.23 -112.36 -97.78
FY   -1,382.02 -3,118.41 -391.63 -652.16



NVTA Operating Income third quarter 2023 Y/Y Growth Comment
Invitae Corporation in the third quarter 2023 recorded Operating Loss of $ -980.19 millions.

According to the results reported in the third quarter 2023, Invitae Corporation achieved the best Operating Income growth in Medical Laboratories industry. While Invitae Corporation' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2023.

Explain Operating Income growth


NVTA Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Invitae's third quarter 2023 Operating Income $ -980.19 millions NVTA's Income Statement
Invitae's third quarter 2022 Operating Income $ -289.95 millions Quarterly NVTA's Income Statement
New: More NVTA's historic Operating Income Growth >>


NVTA Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Invitae's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NVTA's III. Quarter Q/Q Operating Income Comment
Recent results of -980.19 millions by Invitae Corporation come out even more unfavourable considering the -226.46 millions Operating Loss in the previous quarter.

Within Medical Laboratories industry Invitae Corporation achieved highest sequential Operating Income growth. While Invitae's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NVTA's III. Quarter Q/Q Operating Income Comment
III. Quarter 2023 results of -980.19 millions by Invitae Corporation look even more unfavourable if you take a look at Operating Loss -226.46 millions in the second quarter.

Within Medical Laboratories industry Invitae Corporation achieved highest sequential Operating Income growth. While Invitae's Operating Income growth quarter on quarter, overall rank is .


Invitae's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -1,476.92 $ -786.68 $ -3,080.55 $ -3,118.41 $ -3,238.09
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment


Invitae Corporation achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment


Invitae Corporation achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Medical Laboratories Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
NVTA's Operating Income Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for NVTA's Competitors
Operating Income Growth for Invitae's Suppliers
Operating Income Growth for NVTA's Customers

You may also want to know
NVTA's Annual Growth Rates NVTA's Profitability Ratios NVTA's Asset Turnover Ratio NVTA's Dividend Growth
NVTA's Roe NVTA's Valuation Ratios NVTA's Financial Strength Ratios NVTA's Dividend Payout Ratio
NVTA's Roa NVTA's Inventory Turnover Ratio NVTA's Growth Rates NVTA's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Ligand Pharmaceuticals Incorporated383.96%$ 383.962 millions
Organogenesis Holdings Inc 352.50%$ 352.501 millions
Puma Biotechnology Inc 258.75%$ 258.755 millions
Electromed Inc 222.73%$ 222.727 millions
National Healthcare Corp219.40%$ 219.397 millions
Amphastar Pharmaceuticals Inc 212.89%$ 212.890 millions
Viemed Healthcare Inc 186.32%$ 186.317 millions
Penumbra Inc 132.33%$ 132.333 millions
Alpha Pro Tech Ltd 119.94%$ 119.938 millions
Collegium Pharmaceutical Inc 119.93%$ 119.930 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com